

Brain Cortex Reverse Triiodothyronine (rT₃) and Triiodothyronine Concentrations under Steady State Infusions of Thyroxine and rT₃

MICHEL O. GOUMAZ, CATHERINE A. KAISER, AND ALBERT G. BURGER

Thyroid Research Unit, Endocrine Division, Department of Medicine, University of Geneva, Switzerland

ABSTRACT. T₄ and reverse T₃ (rT₃) can inhibit 5'-deiodinase type II activity in rat brain cortex, pituitary, and brown adipose tissue, raising the possibility that T₄ may act *in vivo* after conversion to rT₃. The aim of this study was to measure in hypothyroid (Tx) rats the content of brain cortex rT₃ during a constant 7-day infusion of either [¹²⁵I]T₄ alone, corresponding to 12 pmol T₄/day·100 g body weight (BW), or together with 400 pmol T₄/day. [¹²⁵I]T₄, rT₃, and T₃ were extracted from brain cortex, pituitary, kidney, and liver with a combination of adsorption chromatography on Sephadex G-25, HPLC, and immunoprecipitation. [¹³¹I]T₄, T₃, or rT₃ were used as internal standards.

[¹²⁵I]rT₃ could be detected in brain cortex, liver, and kidney in Tx rats infused with [¹²⁵I]T₄ (12 pmol T₄/day·100 g BW) and in those infused with 400 pmol T₄/day·100 g BW. The highest

rT₃ concentrations were found in brain cortex, where it represented 6% to 10.5% of the local T₄ concentration.

During an infusion of 400 pmol T₄/day·100 g BW, brain cortex T₃ concentration was 6 times higher in the brain cortex than in serum, and even exceeded that of T₄. In Tx rats receiving [¹²⁵I]T₄ alone the brain cortex to serum T₃ ratio was 3:1, but the total serum T₃ concentration, measured by RIA, was much higher than that due to conversion [0.50 ± (SE) 0.1 pmol/ml *vs.* 0.018 ± 0.002 pmol T₃/ml], indicating thyroidal secretion.

The effect of the blood-brain barrier on rT₃ was measured by infusing [¹²⁵I]rT₃ over 4 days. After killing, rT₃ was isolated as above. Approximately 3% of serum rT₃ was retrieved from the brain cortex, whereas during the T₄ infusion 40–50% of serum rT₃ was found demonstrating that brain cortex rT₃ is locally produced. (*Endocrinology* 120: 1590–1596, 1987)

MOST of the intracellular T₃ in brain cortex and pituitary is locally produced by the 5'-monodeiodination of T₄ (1–4). The enzyme involved is called the 5'-deiodinase type II (5'D-II) (5–9). It can also be found in placenta and brown adipose tissue. It is particularly active in tissues of hypothyroid rats (10–12) and can be rapidly inhibited by single injections of T₄, T₃, reverse T₃ (rT₃) (13) and 3',5'-diiodothyronine (T₂) (14).

In earlier studies, our group established that a continuous infusion of rT₃ exerted its inhibitory effect at a serum concentration of 7 pmol/ml (15). Concentrations of this magnitude are not encountered in pathophysiological conditions. However, under physiological conditions rT₃ is probably produced locally, explaining why our earlier studies underestimated the concentration of rT₃ present in the brain cortex. The work of Obregon *et al.* (16) supports the hypothesis of local production.

The present investigations confirm and extend the studies of Obregon *et al.* (16), and allow speculations on the physiological role of brain rT₃ as an inhibitor of the conversion of T₄ to T₃.

Received February 14, 1986.

Address requests for reprints to: Miss C. A. Kaiser, Thyroid Research Unit, Hôpital Cantonal, CH 1211-Geneva 4, Switzerland.

*This study was supported by Swiss National Foundation Grant 3.943.0.84.

Materials and Methods

Reagents

The iodothyronines (T₄, T₃, and rT₃) were purchased from Henning Co. (West Berlin, West Germany). Carrier-free Na ¹²⁵I and Na ¹³¹I were obtained from the Institut für Reaktorforschung (Würenlingen, Switzerland). Chloramine-T was used to iodinate rT₃, T₄, and T₃ with ¹²⁵I or ¹³¹I. Low specific activity (SA) of T₄ (54 μCi/μg) was obtained by addition of an adequate amount of unlabeled T₄ (17, 18). Osmotic minipumps (Alzet no. 2001, Alza, London, UK) were used for infusions. HPLC was performed with equipment using a reverse phase Bondapak C18 column (Waters Associates, Milford, MA). TLC was performed on Merck Silicagel 60 F 254 aluminium sheets, with chloroform-methanol-formic acid (16:3:1) used as solvents.

In vivo procedures

Male SIVZ rats, a strain derived from the Wistar rat, were purchased from the breeder (Tierzuchtanstalt, University of Zürich, Zürich, Switzerland) and were rendered hypothyroid (Tx) by thyroidectomy when they reached 150–200 g body weight (BW). The minipumps were implanted on the seventh day after operation, and the animals were killed 1 week later. Two days before and during the experiments, they received 20 mg potassium iodide/liter in their drinking water.

Infusions

Three types of experiments were performed. In Exp I, the minipumps were filled with [^{125}I] T_4 of high SA (2000 $\mu\text{Ci}/\mu\text{g}$), which was infused at a rate of 12 pmol $T_4/\text{day} \cdot 100 \text{ g BW}$ (9.3 ng T_4/day). [^{125}I] T_4 was dissolved in 0.02 N NaOH, 0.05 M sodium carbonate, 0.9% NaCl, and 10% Tx rat serum. Four Tx rats received infusions for 7 days.

In Exp II, the minipumps were filled with [^{125}I] T_4 of low SA (54 $\mu\text{Ci}/\mu\text{g}$), which was infused at a rate of 400 pmol/day $\cdot 100 \text{ g BW}$ (311 ng T_4/day). The infusion also lasted 7 days. Eight Tx rats were used.

In Exp III, the Tx rats received [^{125}I] rT_3 . The minipumps were filled with [^{125}I] rT_3 with a SA of 900 $\mu\text{Ci}/\mu\text{g}$, which was infused at a rate of 100 pmol $rT_3/\text{day} \cdot 100 \text{ g BW}$ (54 ng rT_3/day). Four Tx rats received infusions for 3 days.

Before implantation, the minipumps were left to equilibrate overnight at room temperature in 0.9% NaCl, 1% BSA, and then implanted ip. At the end of the infusion the animals were killed by abdominal aortic exsanguination under light ether anesthesia. To reduce plasma contamination of the tissues, the rats were gently perfused with 25–30 ml ice-cold 0.9 NaCl containing 0.1 mM propylthiouracil (PTU) and 1 mM iopanoic acid via the opening in the aorta. Outflow was obtained by puncturing the inferior vena cava. The heart continued pumping the infused medium until the end of the procedure. The liver, kidneys, cerebral cortex, and anterior pituitary of each animal were rapidly removed, frozen immediately in liquid nitrogen, and kept at -70°C until processed.

In order to measure the degradation of [^{125}I] T_4 and [^{125}I] rT_3 during the 3 or 7 days of infusion, the minipumps were placed for 4 h in 0.9% NaCl, 1% BSA, 10 mM PTU, and 0.5 mM iopanoic acid. Aliquots of this and of the initial solutions were analyzed by chromatography on Sephadex G-25. During the infusions about 10% of the iodine in T_4 was released as I^- , and about 20% of that in rT_3 .

Extraction procedures

In vitro degradation of the iodothyronines was always measured by addition of their ^{131}I -labeled tracers. 5'-Monodeiodination of rT_3 is very active in the liver and the kidney and had to be inhibited rapidly (see below). *In vitro* degradation in the brain cortex and pituitary could be inhibited by serum. In these organs the iodothyronines were therefore extracted by immunoprecipitation. This method was also used for extraction of the more stable T_3 in liver and kidney homogenates.

The procedure of rapid denaturation of proteins and extraction by column chromatography is illustrated in Flow Chart 1. Homogenization was performed in a solution consisting of 0.02 N NaOH, 5 mM PTU, 0.5 mM iopanoic acid, 1% Triton X-100, and approximately 10,000 cpm [^{131}I] rT_3 (alkaline solution). A small aliquot (0.5 ml) was frozen for later extraction of T_4 (Chart 1a). Eight milliliters of the homogenate were extracted on a column of Sephadex G-25 (30-ml bed volume in a 60-ml syringe, equilibrated with 0.02 N NaOH, 1% Triton X-100) (Chart 1b). After addition of the homogenate, the columns were rinsed with 30 ml 2 N acetic acid and 40 ml distilled water. The labeled hormones were eluted with 95 ml 0.02 N NaOH. The eluate was acidified with 4 ml acetic acid. This solution was

CHART 1. rT_3 extraction from liver and kidney, T_4 extraction from liver and kidney.





CHART 2. Extraction and immunoprecipitation of T_4 , T_3 , and rT_3 from brain cortex, pituitary, liver, and kidney.



passed through a Dowex 50 WX2 cation exchange column equilibrated with 1.74 N acetic acid (1-ml bed volume in a 2-ml syringe). After washing of the column with 8 ml acetone- H_2O (1:1), the hormones were eluted with 3 ml 7 N NH_4OH -ethanol (7:3) and dried under vacuum. The recovery of [^{131}I] rT_3 was 85%. HPLC was performed according to the method of Van Der Walt and Cahnmann (19), with use of an acetonitrile gradient from 25% to 50% in 20 mM ammonium acetate, pH 4.

Immunoprecipitation (Chart 2) was performed in 25 mM Tris-HCl buffer, pH 8.2, 0.0036% NaCl, 10% human serum (HS), 5 mM PTU, 0.5 mM iopanoic acid (Tris-HCl-HS buffer), and appropriate amounts of [^{131}I] standards of the iodothyronines. The immunoprecipitations were adapted from the

method of Engler *et al.* (20).

One hundred to 200 μ l homogenate were incubated for T₄ immunoprecipitation. For the liver and kidney, the alkaline solution was first neutralized with 0.1 N HCl and 200 μ l Tris-HCl-HS buffer (Chart 1a). Serum binding was inhibited with 8-anilino-naphthalene-1-sulfonic acid (14 μ g/100 μ l Tris-HCl-HS buffer), and T₄ was precipitated with 20 μ l rabbit anti-T₄ serum (1:10).

For T₃ and rT₃ 1 to 3 times 2 ml homogenate were incubated with 200 μ g 8-anilino-naphthalene-1-sulfonic acid. To ensure maximum extraction of T₃ and rT₃, each sample was incubated with both antisera [20 μ l rabbit anti-T₃ (1:10) and 60 μ l anti-rT₃ serum (1:10)].

The incubations were identical for all types of immunoprecipitations. The samples were kept at 37 C for 10 min and at 4 C overnight. Bound and free hormones were separated by precipitation with a goat antirabbit antiserum (Antibodies Inc., Davies, CA). As the immunoprecipitates could not be injected as such into the HPLC column, the proteins were eliminated on the Dowex column (see above). T₃ and rT₃ were then separated by HPLC and T₄ by TLC. The recoveries of [¹³¹I]T₄, [¹³¹I]T₃, and [¹³¹I]rT₃ were 83 \pm 3% (mean \pm SE).

Serum T₄, T₃ and rT₃ were also extracted by immunoprecipitation, as adapted from Engler *et al.* (20). In addition, the pellets of immunoprecipitated hormones were further processed as above, with the use of a Dowex 50 WX2 column to eliminate the proteins. The T₄ extracts were then chromatographed by TLC, whereas rT₃ and T₃ extracts were analyzed by HPLC.

Degradation of rT₃ during tissue preparation

In order to evaluate rT₃ degradation during tissue preparation, we injected three groups of Tx rats (thyroidectomized 4 weeks previously) iv via the jugular vein with 10 μ Ci [¹²⁵I]rT₃ (Amersham, Buckinghamshire, UK; SA 1200 μ Ci/ μ g) dissolved in 0.02 N NaOH and diluted with 10% rat serum in 0.9% NaCl. After 30 min, the rats were killed as previously described. In the first group, the liver was immediately removed and frozen. In the second and third groups, we waited 1 and 3 min, respectively, before removing the liver. Cerebral cortices were removed immediately after the liver, so that the time interval was also 1 and 3 min between the groups. Tissues and serum were processed as above. Dissection time did not affect the rT₃ content of the two tissues (Table 1).

Calculations and statistical analysis

As in the Tx rats, endogenous serum T₄ levels were undetectable and the SA of the infused T₄ was identical with that in serum and tissues. Serum T₄ concentration could therefore

TABLE 1. Tissue to serum [¹²⁵I]rT₃ ratio (Exp IV)

Time between perfusing of the animal and removal of the organ	Liver	Cerebral cortex
Group 1: 0 min	27.1 \pm 6.1%	5.36 \pm 0.87%
Group 2: 1 min	27.9 \pm 6.7%	5.03 \pm 0.37%
Group 3: 3 min	27.3 \pm 5.4%	5.87 \pm 0.37%

Values are given as mean \pm SE.

be measured by RIA or calculated from its SA. Serum rT₃ and T₃ could also be calculated from the SA of [¹²⁵I]T₄, taking into account that [¹²⁵I]T₄ was labeled in the 3' or 5'-position. Hence, only one out of two T₄ molecules converted to T₃ was radioactive, reducing the SA of [¹²⁵I]T₃ to half that of [¹²⁵I]T₄. The SA of [¹²⁵I]rT₃ was the same as that of T₄. The percent T₃ due to conversion was calculated from the ratio of the serum T₃ concentration due to conversion and the serum T₃ concentration measured by RIA.

Student's *t* test for means and Wilcoxon's test (if *n* > 7) were used to assess the significance of any observed difference. The values are given as means \pm SE.

Results

During infusion of 400 pmol T₄/day \cdot 100 g BW, serum T₄ concentration measured by RIA was 40.3 \pm 1.7 pmol/ml, which was very similar to the serum T₄ level of 38.6 \pm 3.6 pmol/ml (30 ng/ml) calculated from the SA of the infused T₄ (Table 2). Table 2 shows that T₄ concentration was much lower in the brain cortex than in serum, whereas liver and kidney T₄ concentrations were substantial, although below the serum T₄ concentration. Pituitary and serum T₄ concentrations did not differ.

In the same experiment serum T₃ concentration was 0.89 \pm 0.17 pmol/ml (0.58 ng/ml) measured by RIA and 0.65 \pm 0.07 pmol/ml (0.42 ng/ml; Table 3) calculated on the basis of its SA. A large proportion of the circulating T₃ could therefore be attributed to conversion.

Based on the SA of T₃, the highest concentration of T₃ was found in the pituitary, followed by brain cortex and kidney. T₃ concentration in the liver was markedly lower, but nevertheless 4 times higher than in serum.

TABLE 2. T₄ concentrations per ml serum or g tissue during T₄ infusion

	Serum	Brain cortex	Pituitary	Liver	Kidney
a) 400 pmol T ₄ /day \cdot 100 g BW					
	pmol T ₄ /ml serum or g tissue				
n	8	8	8	8	8
Mean	38.6	1.91	44.9	30.1	19.1
SE	3.6	0.14	7.3	2.4	0.7
P ^a		0.001	NS	NS	0.001
	ng T ₄ /ml serum or g tissue				
Mean	30.0	1.48	34.9	23.4	14.8
b) 12 pmol T ₄ /day \cdot 100 g BW					
	pmol T ₄ /ml serum or g tissue				
n	4	4	3	4	4
Mean	2.16	0.041	0.79	0.62	0.48
SE	0.13	0.005	0.09	0.03	0.02
P ^a		0.05	0.05	0.05	0.05
	ng T ₄ /ml serum or g tissue				
Mean	1.68	0.032	0.61	0.48	0.37

NS, Not significant (<0.05).

^a Significance compared to serum values.

TABLE 3. T_3 concentrations per ml serum or g tissue during T_4 infusion

	Serum	Brain cortex	Pituitary	Liver	Kidney
a) 400 pmol T_4 /day · 100 g BW					
	pmol T_3 /ml serum or g tissue				
n	8	8	8	8	8
Mean	0.650	3.948	5.700	2.712	3.798
SE	0.070	0.283	0.515	0.198	0.223
P^a		0.001	0.001	0.001	0.001
	ng T_3 /ml serum or g tissue				
Mean	0.423	2.570	3.711	1.766	2.472
b) 12 pmol T_4 /day · 100 g BW					
	pmol T_3 /ml serum or g tissue				
n	4	4		4	4
Mean	0.018	0.064		0.035	0.063
SE	0.001	0.010		0.004	0.002
P^a		0.050		0.05	0.05
	ng T_3 /ml serum or g tissue				
Mean	0.012	0.042		0.023	0.041

^a Significance compared to serum values.TABLE 4. rT_3 concentrations per ml serum or g tissue during T_4 infusion

	Serum	Brain cortex	Liver	Kidney
a) 400 pmol T_4 /day · 100 g BW				
	pmol rT_3 /ml serum or g tissue			
n	8	7	7	8
Mean	0.276	0.114	0.216	0.184
SE	0.029	0.013	0.021	0.010
P^a		0.001	NS	0.01
	ng rT_3 /ml serum or g tissue			
Mean	0.179	0.074	0.141	0.120
b) 12 pmol T_4 /day · 100 g BW				
	pmol rT_3 /ml serum or g tissue			
n	4	4	4	2
	0.0079	0.0043	0.0300	0.0266
SE	0.0006	0.0007	0.0112	
P^a		0.05	0.05	
	ng rT_3 /ml serum or g tissue			
Mean	0.0051	0.0028	0.0195	0.0173

NS, Not significant (>0.05).^a Significance compared to serum values.

The highest concentration of rT_3 was found in serum. Brain cortex, kidney, and liver rT_3 concentrations amounted to 41%, 67%, and 78% of serum levels, respectively (Table 4).

In Fig. 1 serum or tissue T_3 and rT_3 concentrations are expressed as percentages of local T_4 concentrations. The figure clearly shows the peculiarity of the brain cortex, with a T_3 concentration exceeding that of T_4 . Although rT_3 did not exceed 6% of T_4 , the highest ratio of rT_3 to T_4 was also found in brain cortex.




FIG. 1. T_4 was infused at a rate of 400 pmol T_4 /day · 100 g BW. The resulting concentrations of $[^{125}I]rT_3$ and $[^{125}I]T_3$ are represented as percentages of the $[^{125}I]T_4$ concentration in the same tissue or serum. Clearly marked differences between tissues are seen. For both rT_3 and T_3 , the highest percentage is found in the brain cortex.

With infusions of 12 pmol T_4 /day · 100 g BW (Table 2), serum T_4 levels were similar whether they were measured by RIA (2.3 ± 1.3 pmol/ml or 1.8 ng/ml) or calculated on the basis of the infusion rate (2.16 ± 0.13 pmol/ml or 1.7 ng/ml). The T_4 concentrations in the brain cortex were again small compared to those in the serum and the other tissues that were studied. In these still severely Tx animals T_3 measured by RIA differed markedly from T_3 resulting from conversion. Serum T_3 was 0.50 ± 0.10 pmol/ml (0.33 ng/ml) when measured by RIA, whereas serum T_3 due to conversion [0.018 ± 0.002 pmol/ml or 0.012 ng/ml (Table 3)] only amounted to 3.6% of the circulating T_3 level. Its distribution in serum and tissue was calculated on the basis of its SA and was comparable to the distribution observed during infusion of 400 pmol T_4 /day · 100 g BW, the highest concentrations being found in brain cortex and renal tissue. The pituitary was not studied. The concentration of T_3 in brain cortex was again higher than the concentration of T_4 . During the infusion of 12 pmol T_4 /day · 100 g BW the highest concentrations of rT_3 were found in liver and kidney (Table 4). Tissue rT_3 to T_4 ratio in brain cortex

was higher than in the other two tissues. Pituitary rT_3 concentration was too low for detection.

Infusion rates in terms of counts per min $[^{125}I]T_4$ were identical in both experiments. However, Fig. 2 shows that the serum levels of infused $[^{125}I]T_4$ differ markedly according to whether 400 or 12 pmol T_4 /day · 100 g BW were infused. The higher $[^{125}I]T_4$ serum level during an infusion of 12 pmol T_4 /day · 100 g BW indicated a lower plasma clearance rate than during an infusion of 400 pmol T_4 /day · 100 g BW (0.47 ± 0.03 ml/h · 100 g BW *vs.* 0.91 ± 0.07 ml/h · 100 g BW). However, the brain cortex and kidney count per min/ $[^{125}I]T_4$ per g tissue were not affected by the infusion of 400 pmol T_4 /day · 100 g BW, and during this infusion there was a significant increase in the hepatic $[^{125}I]T_4$ concentration.

During the $[^{125}I]rT_3$ infusion its calculated serum level was 0.028 ± 0.03 pmol/ml (0.02 ng/ml), yielding a plasma clearance rate of 78 ± 8 ml/h · 100 g BW. $[^{125}I]rT_3$ was unmeasurable in the pituitary and was also low in brain cortex. In Table 5 results are also expressed as percentages of serum $[^{125}I]rT_3$ values. They show that $[^{125}I]rT_3$ in the brain cortex represented only 3.3% of serum $[^{125}I]rT_3$. In the liver and kidney the values were 71% and 38% of serum rT_3 concentration, the difference between liver and kidney being significant ($P < 0.05$).

Discussion

Iodothyronines with two iodine atoms on the phenolic ring (T_4 , rT_3 , and $3',5'-T_2$) are the most potent inhibitors of the high 5'D-II activity Tx rats. These iodothyronines,

and rT_3 in particular, are also capable of inhibiting the activity of this enzyme in cell cultures in the absence of thyroid hormones (22–24).

There is little doubt that T_4 is the major 5'D-II inhibitor *in vivo*. However, the question of whether T_4 acts directly or after conversion to rT_3 remains unresolved. Ideally, a specific inhibitor of the enzyme converting T_4 to rT_3 in brain tissue, placenta and skin, the so called 5-deiodinase type III (25, 26), would provide the answer, but unfortunately no such compound is available. Knowledge of brain cortex rT_3 concentrations could also throw light on the problem. Obregon *et al.* (16) have already addressed this question. Their estimation of brain cortex rT_3 concentration was based on the single injection technique. Our earlier studies with continuous infusions of rT_3 and T_4 established the serum concentrations of rT_3 and T_4 required to inhibit 5'D-II activity to the same extent. The question therefore arose of the brain cortex rT_3 concentrations in the two types of experiments, and the present study was designed to answer it. We studied serum and brain cortex rT_3 concentrations during T_4 infusion and estimated the extent to which the rT_3 blood brain barrier excludes rT_3 during an infusion of the hormone. The results of the T_4 infusion showed that for serum levels of 40 pmol T_4 /ml the rT_3 concentration was 0.114 pmol/g in the brain cortex and 0.276 pmol/ml in serum. The concentration of rT_3 in the brain cortex is therefore approximately 40% that of rT_3 in serum. However, during continuous infusions of $[^{125}I]rT_3$, brain cortex rT_3 concentration was only 3.3% of its serum concentration. We therefore infer that most of the rT_3 found in




FIG. 2. Tissue or serum $[^{125}I]T_4$ concentrations (counts per min $\times 10^6$ /g or ml) during $[^{125}I]T_4$ infusion in the absence (\square , $n=4$) or presence of 400 pmol T_4 /day · 100 g BW (\square , $n=8$). Results are expressed as mean \pm SE.

TABLE 5. Infusion of [¹²⁵I]rT₃

	Serum	Brain cortex	Liver	Kidney
cpm rT ₃ /g tissue or ml serum				
n	4	4	4	4
Mean	25108	805	17970	9480
SE	2555	28	3648	1409
P ^a		<0.05	NS	<0.05
cpm rT ₃ /g tissue expressed as % cpm in serum				
n		4	4	4
Mean		3.3%	71.0%	37.8%
SE		0.4%	10.5%	5.1%

NS, Not significant (>0.05).

^a Significance compared to serum values.

the brain cortex results from local conversion of T₄ to rT₃. On the other hand, the quantity of infused rT₃ required to inhibit brain cortex 5'D-II activity to the same extent as 400 pmol T₄/day·100 g BW has been established (15) as 13.5 nmol/day·100 g BW, yielding a serum level of 7 pmol rT₃/ml. On the basis of the present experiments, brain cortex rT₃ corresponding to a serum concentration of 7 pmol/ml can be predicted to be 0.24 pmol/g tissue. This value is not dissimilar to the measured value of 0.114 pmol rT₃/g, and suggests that brain cortex rT₃ concentration contributes to *in vivo* inhibition of 5'D-II by T₄.

No corrections were made for trapped plasma in cerebral cortex which, according to Silva and Matthews (27), is less than 1%. Yet, as indicated above, only small amounts of infused rT₃ (3.3%) could be found in brain cortex homogenates. Our values of brain cortex rT₃ concentration during the infusion of [¹²⁵I]rT₃ may therefore be slightly overestimated, whereas during the infusion of [¹²⁵I]T₄ the brain cortex concentration of [¹²⁵I]rT₃ is much too high to be affected by a contamination by plasma rT₃. The error due to trapped plasma is certainly greater in the highly vascularized liver and kidney.

The tissue T₃ concentrations observed confirm earlier work (1–4). They also show that in the presence of low to moderate serum T₄ brain cortex T₃ concentration is even greater than brain cortex T₄ concentration. This can mainly be attributed to local conversion, although we have clearly demonstrated that the efficiency of brain cortex T₄ to T₃ conversion in hypothyroidism does not increase sufficiently to maintain brain cortex T₃ concentrations in the euthyroid range. Using measurements based on the conversion of unlabeled T₄, brain cortex T₃ concentrations in Tx rats reached only 1.5% of the concentrations in rats infused with 400 pmol T₄/day·100 g BW. In Tx rats serum T₃ values measured by RIA were greater than those measured as having arisen by conversion, indicating thyroidal secretion of T₃. This T₃ diffuses into brain cortex, thus increasing brain tissue concentra-

tions, although it may be limited by the blood-brain barrier.

Acknowledgment

We thank Dr. Carol Liniger for reviewing the English.

References

1. Van Doorn J, Roelfsema F, Van Der Heide D 1982 Contribution from local conversion of thyroxine to 3,5,3'-triiodothyronine to intracellular 3,5,3'-triiodothyronine in several organs in hypothyroid rats at isotope equilibrium. *Acta Endocrinol (Copenh)* 101:386
2. Van Doorn J, Van Der Heide D, Roelfsema F 1983 Sources and quantity of 3,5,3'-triiodothyronine in several tissues of the rat. *J Clin Invest* 72:1778
3. Van Doorn J, Roelfsema F, Van Der Heide D 1985 Concentrations of thyroxine and 3,5,3'-triiodothyronine at 34 different sites in euthyroid rats as determined by an isotopic equilibrium technique. *Endocrinology* 117:1201
4. Crantz FR, Larsen PR 1980 Rapid thyroxine to 3,5,3'-triiodothyronine conversion and nuclear 3,5,3'-triiodothyronine binding in rat cerebral cortex and cerebellum. *J Clin Invest* 65:935
5. Visser TJ, Leonard JL, Kaplan MM, Larsen PR 1982 Kinetic evidence suggesting two mechanisms for iodothyronine 5'-deiodination in rat cerebral cortex. *Proc Natl Acad Sci USA* 79:5080
6. Visser TJ, Leonard JL, Kaplan MM, Larsen PR 1981 Different pathways of iodothyronine 5'-deiodination in rat cerebral cortex. *Biochem Biophys Res Commun* 101:1297
7. Visser TJ, Kaplan MM, Leonard JL, Larsen PR 1983 Evidence for two pathways of iodothyronine 5'-deiodination in rat pituitary that differ in kinetics, propylthiouracil sensitivity, and response to hypothyroidism. *J Clin Invest* 71:992
8. Leonard JL, Mellen SA, Larsen PR 1983 Thyroxine 5'-deiodinase activity in brown adipose tissue. *Endocrinology* 112:1153
9. Kaplan MM, Shaw E 1984 Type II iodothyronine 5'-deiodination by human and rat placenta *in vitro*. *J Clin Endocrinol Metab* 59:253
10. Silva EJ, Gordon MB, Crantz FR, Leonard JL, Larsen PR 1984 Qualitative and quantitative differences in the pathways of extra-thyroidal triiodothyronine generation between euthyroid and hypothyroid rats. *J Clin Invest* 73:898
11. Kaplan MM 1970 Thyroxine 5'-monodeiodination in rat anterior pituitary homogenates. *Endocrinology* 106:567
12. Kaplan MM, Yaskoski K 1980 Phenolic and tyrosyl ring iodothyronine deiodination in rat brain homogenates. *J Clin Invest* 66:551
13. Silva EJ, Leonard JL 1985 Regulation of rat cerebrocortical and adenohypophyseal type II 5'-deiodinase by thyroxine, triiodothyronine, and reverse triiodothyronine. *Endocrinology* 116:1627
14. Silva EJ, Leonard JL, Larsen PR, Relative *in vivo* potency of iodothyronines to inhibit cerebral cortex (cx) and pituitary (p) iodothyronine 5'-deiodinase activity in hypothyroid (h) rats. Program of the 65th Annual Meeting of the Endocrine Society, San Antonio, TX, 1983, p 202 (Abstract)
15. Kaiser CA, Goumaz MO, Burger AG 1986 *In vivo* inhibition of the 5'-deiodinase type II in brain cortex and pituitary by reverse triiodothyronine. *Endocrinology* 119:762
16. Obregon MJ, Larsen PR, Silva EJ 1985 Plasma kinetics, tissue distribution, and cerebrocortical sources of reverse triiodothyronine in the rat. *Endocrinology* 116:2192
17. Burger AG, Ingbar SH 1974 Labelling of thyroid hormones and their derivatives. *Endocrinology* 94:1189
18. Kochupillai N, Yalow RS 1978 Preparation, purification, and stability of high specific activity [¹²⁵I]labelled thyronines. *Endocrinology* 102:128
19. Van Der Walt B, Cahnmann HJ 1982 Synthesis of thyroid hormone metabolites by photolysis of thyroxine and thyroxine analogs in the near uv. *Proc Natl Acad Sci USA* 79:1492
20. Engler D, Merkelbach U, Steiger G, Burger A 1984 The monodeiodination of triiodothyronine and reverse triiodothyronine in man:

- a quantitative evaluation of the pathway by the use of turnover rate techniques. *J Clin Endocrinol Metab* 58:49
21. Deleted in proof
 22. St Germain DL 1985 Metabolic effect of 3,3',5'-triiodothyronine in cultured growth hormone-producing rat pituitary tumor cells: evidence for a unique mechanism of thyroid hormone action. *J Clin Invest* 76:890
 23. Cavalieri RR, Gavin LA, Cole R, De Vellis J 1986 Thyroid hormone deiodinases in purified primary glial cell cultures. *Brain Res* 364:382
 24. Leonard JL, Silva JE, Kaplan MM, Mellen SA, Visser TJ, Larsen PR 1984 Acute posttranscriptional regulation of cerebrocortical and pituitary iodothyronine 5'-deiodinases by thyroid hormone. *Endocrinology* 114:998
 25. Huang TS, Chopra IJ, Beredo A, Solomon DH, Chua Teco GN 1985 Skin is an active site for the inner ring monodeiodination of thyroxine to 3,3',5'-triiodothyronine. *Endocrinology* 117:2106
 26. Ködding R, Fuhrmann H, Von zur Mühlen A 1986 Investigations on iodothyronine deiodinase activity in the maturing rat brain. *Endocrinology* 118:1347
 27. Silva JE, Matthews PS 1984 Production rate and turnover of triiodothyronine in rat- developing cerebral cortex and cerebellum. Responses to hypothyroidism. *J Clin Invest* 74:1035